27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
- Coherus BioSciences Inc (NASDAQ:CHRS) announced results from a bioequivalence study of Udenyca (pegfilgrastim-cbqv) administered via a proprietary on-body injector (OBI) device compared to the currently marketed Udenyca pre-filled syringe (PFS).
- The study met all PK bioequivalence primary endpoints and the key secondary pharmacodynamic endpoint of ANC (absolute neutrophil count).
- No new safety signals were observed.
- The study enrolled 189 subjects randomized 1:1 to receive one of two treatment sequences of Udenyca OBI followed by PFS, or the reverse, with a treatment interval of 6 to 8 weeks.
- Coherus plans a 2022 submission to the FDA of a prior approval supplement to seek marketing authorization for the UDENYCA® OBI and anticipates a standard 10-month review period.
- Coherus expects the commercial launch of the Udenyca OBI directly post-approval.
- Udenyca is a leukocyte growth factor indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies.
- Price Action: CHRS stock is up 4.11% at $16.46 during the market session on the last check Tuesday.
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!